Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Colorectal Disease
Published in: International Journal of Colorectal Disease 9/2015

01-09-2015 | Original Article

The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage II colorectal cancer

Authors: Tsuyoshi Ozawa, Soichiro Ishihara, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Kazushige Kawai, Hiroaki Nozawa, Shinsuke Kazama, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe

Published in: International Journal of Colorectal Disease | Issue 9/2015

Login to get access

Abstract

Purpose

The platelet to lymphocyte ratio (PLR) is a potential prognostic marker in a number of different cancers. The aim of this study was to evaluate the prognostic impact of the PLR in patients with stage II colorectal cancer (CRC) who have undergone curative resection but not adjuvant chemotherapy.

Methods

A retrospective review was performed on 234 patients with stage II CRC who underwent curative resection, but not adjuvant chemotherapy, in our institute. The patients were divided into low and high PLR groups, and patient survival as well as several clinicopathological factors were compared between the groups. Disease-free survival (DFS) and cancer-specific survival (CSS) were analyzed by using the Kaplan–Meier method, and multivariate analysis was performed by using the Cox proportional hazard model.

Results

The cutoff value of the PLR determined by using a receiver-operating characteristic curve analysis was 25.4. DFS and CSS were significantly better in patients with a low PLR compared to patients with a high PLR (P = 0.002 and P = 0.011, respectively). On multivariate analysis, we identified the PLR as an independent prognostic factor for DFS and CSS, with a hazard ratio of 2.65 (95 % confidence interval [CI], 1.26–5.45; P = 0.011) and 3.61 (95 % CI, 1.08–12.64; P = 0.038, respectively).

Conclusions

The PLR is a good prognostic indicator in patients with stage II CRC who have undergone curative surgery but not adjuvant chemotherapy.
Literature
1.
Rodríguez-Moranta F, Saló J, Arcusa A et al (2010) Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol 24:386–393CrossRef
2.
Galizia G, Gemei M, Orditura M et al (2013) Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients. J Gastrointest Surg 17:1809–1818CrossRefPubMed
3.
Bae SJ, Shin US, Ki YJ, Cho SS, Moon SM, Park SH (2014) Role of peritoneal lavage cytology and prediction of prognosis and peritoneal recurrence after curative surgery for colorectal cancer. Ann Coloproctol 30:266–273PubMedCentralCrossRefPubMed
4.
Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797–1806CrossRefPubMed
5.
International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939–944CrossRef
6.
Gray R, Barnwell J, McConkey C et al (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370:2020–2029CrossRefPubMed
7.
Kumar A, Kennecke HF, Renouf DJ, et al (2014) Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer
8.
O'Connor ES, Greenblatt DY, LoConte NK et al (2011) Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 29:3381–3388PubMedCentralCrossRefPubMed
9.
10.
11.
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444CrossRefPubMed
12.
Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123–134CrossRefPubMed
13.
Xie X, Luo KJ, Hu Y, Wang JY, Chen J (2014) Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer. Dis Esophagus
14.
Lee S, Oh SY, Kim SH et al (2013) Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer 13:350PubMedCentralCrossRefPubMed
15.
Smith RA, Bosonnet L, Raraty M et al (2009) Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197:466–472CrossRefPubMed
16.
Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T (2012) Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 23:265–273PubMedCentralCrossRefPubMed
17.
Ying HQ, Deng QW, He BS et al (2014) The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol 31:305CrossRefPubMed
18.
Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–4CrossRefPubMed
19.
Benson AB, Bekaii-Saab T, Chan E et al (2013) Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw 11:519–528
20.
Zhang JX, Song W, Chen ZH et al (2013) Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol 14:1295–1306CrossRefPubMed
21.
Maak M, Simon I, Nitsche U et al (2013) Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg 257:1053–1058CrossRefPubMed
22.
Canna K, McArdle PA, McMillan DC et al (2005) The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 92:651–654PubMedCentralCrossRefPubMed
23.
Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM (1997) Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182:318–324CrossRefPubMed
24.
Kitayama J, Yasuda K, Kawai K, Sunami E, Nagawa H (2010) Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiat Oncol 5:47PubMedCentralCrossRefPubMed
25.
Cézé N, Thibault G, Goujon G et al (2011) Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol 68:1305–1313CrossRefPubMed
26.
Trousseau A, Phlegmasia alba dolens (1865) Lectures on clinical medicine, delivered at the Holte-Dieu. Paris 5:281–332
27.
Sasaki K, Kawai K, Tsuno NH, Sunami E, Kitayama J (2012) Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg 36:192–200CrossRefPubMed
28.
Son HJ, Park JW, Chang HJ et al (2013) Preoperative plasma hyperfibrinogenemia is predictive of poor prognosis in patients with nonmetastatic colon cancer. Ann Surg Oncol 20:2908–2913CrossRefPubMed
29.
Palumbo JS, Talmage KE, Massari JV et al (2005) Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105:178–185CrossRefPubMed
30.
Szkandera J, Pichler M, Absenger G et al (2014) The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients. Am J Surg 208:210–214CrossRefPubMed
31.
Neofytou K, Smyth EC, Giakoustidis A, Khan AZ, Cunningham D, Mudan S (2014) Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Med Oncol 31:239CrossRefPubMed
32.
Baranyai Z, Krzystanek M, Jósa V et al (2014) The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancer. Thromb Haemost 111:483–490CrossRefPubMed
Metadata
Title
The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage II colorectal cancer
Authors
Tsuyoshi Ozawa
Soichiro Ishihara
Takeshi Nishikawa
Toshiaki Tanaka
Junichiro Tanaka
Tomomichi Kiyomatsu
Keisuke Hata
Kazushige Kawai
Hiroaki Nozawa
Shinsuke Kazama
Hironori Yamaguchi
Eiji Sunami
Joji Kitayama
Toshiaki Watanabe
Publication date
01-09-2015
Publisher
Springer Berlin Heidelberg
Published in
International Journal of Colorectal Disease / Issue 9/2015
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-015-2276-9

Other articles of this Issue 9/2015

International Journal of Colorectal Disease 9/2015 Go to the issue

Letter to the Editor

Management of adenomas within the area of rectal cancer that develop complete pathological response

Original Article

Surgical diverticulitis is not associated with defects in the expression of wound healing genes

Original Article

Preoperative prediction of conversion from laparoscopic rectal resection to open surgery: a clinical study of conversion scoring of laparoscopic rectal resection to open surgery

Original Article

A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites

Original Article

Dietary fatty acid intakes are related to the risk of ulcerative colitis: a case–control study

Original Article

Seasonal variation in onset and relapse of IBD and a model to predict the frequency of onset, relapse, and severity of IBD based on artificial neural network